A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

This study provides valuable insight into the increasing use of obesity drugs. The rising prescription numbers suggest that ...

Take a stroll through the aisles of any supermarket, and you will see plenty of other items, including bread, cereal bars and ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...